PROTOCOL SPECIFIC RESEARCH SUPPORT

$379,737P30FY2009CANIH

University Of California, San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 39660606 Paper 39554033 Paper 39387093 Paper 39386732 Paper 39369731 Paper 39288505 Paper 39255776 Paper 39252899 Paper 39198676 Paper 39178841 Paper 39079076 Paper 38992221 Paper 38924428 Paper 38916140 Paper 38907991 Paper 38900207 Paper 38895302 Paper 38895040 Paper 38819840 Paper 38811792 Paper 38678559 Paper 38676932 Paper 38630954 Paper 38562834 Paper 38562778 Paper 38532105 Paper 38496519 Paper 38490196 Paper 38470545 Paper 38463958 Paper 38451815 Paper 38405831 Paper 38389832 Paper 38383439 Paper 38370663 Paper 38370638 Paper 38355413 Paper 38351528 Paper 38328167 Paper 38187712 Paper 38109209 Paper 38082391 Paper 38077055 Paper 38007238 Paper 37992684 Paper 37904046 Paper 37878761 Paper 37749347 Paper 37703185 Paper 37632288 Paper 37425903 Paper 37398204 Paper 37246588 Paper 37235843 Paper 37208512 Paper 37156909 Paper 37147433 Paper 37146605 Paper 37002881 Paper 36929768 Paper 36880536 Paper 36857322 Paper 36700399 Paper 36648492 Paper 36640924 Paper 36520518 Paper 36432661 Paper 36383412 Paper 36373573 Paper 36351060 Paper 36318757 Paper 36307860 Paper 36282590 Paper 36273492 Paper 36264168 Paper 36181350 Paper 36173678 Paper 36127421 Paper 36002574 Paper 35972367 Paper 35929442 Paper 35915160 Paper 35879364 Paper 35875822 Paper 35857628 Paper 35853457 Paper 35737914 Paper 35623341 Paper 35460557 Paper 35434798 Paper 35377797 Paper 35287169 Paper 35262628 Paper 35247883 Paper 35104453 Paper 35101947 Paper 35045815 Paper 35022323 Paper 34963056 Paper 34921112

Abstract

Protocol-Specific Research Support funds are requested to cover salary support for a core group of research nurses and data managers for conduct of high priority, innovative, feasibility and phase I institutional clinical research protocols. Staffing for pilot, feasibility, phase I, or the phase I portion of phase I/I I studies is based on the complexity of the study itself and the increased regulatory reporting of adverse events.

View original record on NIH RePORTER →